Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest
- PMID: 41106380
- PMCID: PMC12774452
- DOI: 10.1016/j.ccell.2025.09.010
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest
Abstract
Tumor-infiltrating bacteria are increasingly recognized as modulators of cancer progression and therapy resistance. We describe a mechanism by which extracellular intratumoral bacteria, including Fusobacterium, modulate cancer epithelial cell behavior. Spatial imaging and single-cell spatial transcriptomics show that these bacteria predominantly localize extracellularly within tumor microniches of colorectal and oral cancers, characterized by reduced cell density, transcriptional activity, and proliferation. In vitro, Fusobacterium nucleatum disrupts epithelial contacts, inducing G0-G1 arrest and transcriptional quiescence. This state confers 5-fluorouracil resistance and remodels the tumor microenvironment. Findings were validated by live-cell imaging, spatial profiling, mouse models, and a 52-patient colorectal cancer cohort. Transcriptomics reveals downregulation of cell cycle, transcription, and antigen presentation genes in bacteria-enriched regions, consistent with a quiescent, immune-evasive phenotype. In an independent rectal cancer cohort, high Fusobacterium burden correlates with reduced therapy response. These results link extracellular bacteria to cancer cell quiescence and chemoresistance, highlighting microbial-tumor interactions as therapeutic targets.
Keywords: Fusobacterium; cancer progression; cell-cycle arrest; chemoresistance; colorectal cancer; epithelial cell-to-cell contacts; host-pathogen interactions; intratumoral bacteria; live-cell confocal imaging; spatial single-cell transcriptomics; tumor microenvironment; tumor-infiltrating bacteria.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.B. is an inventor on US patent application no. PCT/US2018/042966, submitted by the Broad Institute and Dana-Farber Cancer Institute, which covers the targeting of Fusobacterium for the treatment of CRC. S.B., C.D.J., J.L.G.N., and M.A.Z.-R. are inventors on US patent application no. F053-0188USP1/22-158-US-PSP, submitted by the Fred Hutch and MD Anderson Cancer Center, which covers the modulation of cancer-associated microbes.
Figures
References
-
- Yamamoto Y, Kamiya T, Yano M, Huyen VT, Oishi M, Nishio M, Suzuki A, Sunami K, and Ohtani N (2023). Oral Microbial Profile Analysis in Patients with Oral and Pharyngeal Cancer Reveals That Tumoral Fusobacterium nucleatum Promotes Oral Cancer Progression by Activating YAP. Microorganisms 11, 2957. 10.3390/microorganisms11122957. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
